Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced ORMS of the disease

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 9, 2013, Pages

  Landa, Iñigo ^a   Ganly, Ian ^b   Chan, Timothy A ^a,b   Mitsutake, Norisato ^c   Matsuse, Michiko ^c   Ibrahimpasic, Tihana ^b   Ghossein, Ronald A ^a   Fagin, James A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Radiation Oncology   (United States)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROTEIN PATCHED; PROTEIN RET; TELOMERASE REVERSE TRANSCRIPTASE;

ADVANCED CANCER; ANAPLASTIC THYROID CANCER; ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOCYTOMA; ONCOGENE RAS; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PTC GENE; RET GENE; TERT GENE; THYROID CANCER; THYROID CARCINOMA; TUMOR INVASION;

CARCINOMA, PAPILLARY; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENES, RAS; HUMANS; MALE; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; SEVERITY OF ILLNESS INDEX; TELOMERASE; THYROID NEOPLASMS;

EID: 84883711485     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2383     Document Type: Article

References (19)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
2. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611-622.
3. Gonzalez-Suarez E, Flores JM, Blasco MA. Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol Cell Biol. 2002;22:7291-7301.
4. Saji M, Xydas S, Westra WH, et al. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res. 1999;5:1483-1489.
5. Brousset P, Chaouche N, Leprat F, et al. Telomerase activity in human thyroid carcinomas originating from the follicular cells. J Clin Endocrinol Metab. 1997;82:4214-4216.
6. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res. 1997;57:2144-2147.
7. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957-959.
8. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959-961.
9. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110: 6021-6026.
10. Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006;106:1286-1295.
11. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256-1264.
12. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885-4893.
13. Liu X,WuG, Shan Y, Hartmann C, von Deimling A, XingM.Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12:1637-1638.
14. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-1074.
15. Caillou B, Talbot M, Weyemi U, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One. 2011;6:e22567.
16. Saad AG, Kumar S, Ron E, et al. Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab. 2006;91:2672-2677.
17. Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009;106:4519-4524.
18. Castelo-Branco P, Choufani S, Mack S, et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 2013; 14:534-542.
19. Lovejoy CA, Li W, Reisenweber S, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012;8:e1002772.